Fatigue Post Viral
6
3
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition
Characterization, Treatment, and Long-term Follow-up of Fatigued Patients in Primary Care
Mechanisms of Persistent Fatigue
Yoga Versus Health Education for the Treatment of Persistent Fatigue in Patients With Post COVID-19 Syndrome
Stellate Ganglion Block to Treat Long COVID 19 Case Series
COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology